Effect of sequence of administration on the pharmacokinetic interaction between the anticholinergic drug biperiden and [3H]quinuclidinyl benzylate or [3H]N-methylscopolamine in rats.
In rats the pharmacokinetic interactions between the anticholinergic drug biperiden and [3H]quinuclidinyl benzylate ([3H]QNB) or [3H]N-methylscopolamine ([3H]NMS) is affected by the sequence in which the drugs are administered. Drug concentrations in various tissues were determined after intravenous administration of [3H]QNB or [3H]NMS (325 ng kg(-1)). Biperiden (6.4 mg kg(-1)) was administered either 5 min before, concomitantly with or 20 min after injection of [3H]QNB or [3H]NMS. When biperiden was administered concomitantly with or before [3H]QNB, distribution of [3H]QNB among the regions of the brain and other tissues was reduced; at 4 h the ratio of the distribution of [3H]QNB for experimental animals to that for control animals ranged from 0.15 to 0.9. When biperiden was administered after [3H]QNB, the distribution of [3H]QNB in the brain and other tissues was significantly higher than for the other two treatments (P < 0.01). However, for [3H]NMS the sequence of administration had no effect on the distribution of the drug in the brain and other tissues except for the kidney. In-vitro, in crude synaptosomal membranes, the amount of [3H]QNB at 2 h relative to the control concentration at equilibrium was 87% when biperiden was added before [3H]QNB and 56% when biperiden was added after [3H]QNB. In both instances the concentration of [3H]NMS reached equilibrium within 30 min. These findings suggest that the difference between the rate constant of association and dissociation at the possible site of action gives rise to the effect of the sequence of administration on the pharmacokinetic interaction.
Ishizaki
J
J
Hospital Pharmacy, Graduate School of Pharmaceutical Sciences, Kanazawa University, Japan.
Yokogawa
K
K
Nakashima
E
E
Takayasu
T
T
Ohshima
T
T
Ichimura
F
F
D000818:Animals; D001665:Binding Sites; D001712:Biperiden / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001921:Brain / Q000378:metabolism; D018680:Cholinergic Antagonists / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D008297:Male; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D019832:N-Methylscopolamine / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D011813:Quinuclidinyl Benzilate / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000378:metabolism; D014018:Tissue Distribution; D014316:Tritium
D018680:Cholinergic Antagonists; D018727:Muscarinic Antagonists; D011950:Receptors, Cholinergic; D001712:Biperiden; D014316:Tritium; D011813:Quinuclidinyl Benzilate; D019832:N-Methylscopolamine